A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan

Clinical trial NCT06596642 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06596642
Sponsor: Bristol-Myers Squibb
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL

β-Thalassemia Major

Start date: 2024-08-21
Primary completion: 2026-10-01
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.